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Drug-Eluting Balloon Treatment for Infrapopliteal Disease*Thomas T. Tsai, MD, MSCyzxSEE PAGE 1614T he treatment of patients with infrapoplitealdisease has become common in our clinicalpractice as the number of patients with
symptomatic peripheral arterial disease skyrockets,
affecting 12% to 29% of the elderly and as many
as 8 to 10 million Americans (1,2). Contemporary
data suggest that >10% of these patients have crit-
ical limb ischemia (CLI), deﬁned as rest pain, non-
healing wounds, or gangrene (3). Historically,
treatments for CLI have yielded poor results. At 1
year, 25% of patients will be dead, 30% will have
undergone amputation, and only 45% will remain
alive with both limbs (4,5). Given the high comor-
bidity burden of patients with CLI and their
increased risk of complications with open surgery,
endovascular therapy has been advocated as the
preferred treatment (6).
The foundation for an endovascular ﬁrst strategy
emanated from the BASIL (Bypass Versus Angioplasty
in Severe Ischaemia of the Leg) (7) randomized
controlled trial published 10 years ago, which
demonstrated similar amputation-free survival in
patients with CLI suitable for both lower extremity
bypass and endovascular therapy with higher short-
term morbidity with surgery. Since that large semi-
nal randomized controlled trial comparing 2 different
therapies for CLI, there has been an explosion of
smaller single-center, single-arm studies conﬁrming
the procedural success and safety of different inter-
ventional devices with universally high limb salvage*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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revascularization, “no option patients,” enrolled in
gene and cell therapy trials have 1-year limb salvage
rates of >75% to 80% (8–10). Furthermore, primary
patency or binary restenosis has not been associated
with hard outcomes such as limb salvage or quality of
life metrics (11–13).In this issue of JACC: Cardiovascular Interventions,
Zeller et al. (14) studied 76 patients with stenosis,
restenosis, or occlusion of the infrapopliteal arteries
excluding in-stent restenosis suffering from claudi-
cation (n ¼ 16) or critical limb ischemia (n ¼ 60), and
they assessed the safety and performance of the
Passeo-18 Lux paclitaxel coated drug-eluting balloon
(DEB) versus the uncoated Passeo-18 balloon cath-
eter (both Biotronik, Berlin, Germany). Using this
multicenter randomized controlled trial, they
contributed 3 main ﬁndings to the existing published
reports.
1. The primary safety endpoint consisting of mor-
tality, major amputation, treatment thrombosis,
and target vessel revascularization was not sta-
tistically different between DEB and plain balloon
angioplasty (PTA) at 6 months (0% vs. 8.3%,
p ¼ 0.239).
2. Patency loss on 6-month angiography between
DEB and PTA groups was high (20.3% vs. 26.6%),
approaching 50% in both groups and not statisti-
cally different at 1 year (50.8% vs. 45.6%).
3. Despite the loss of patency and high target lesion
revascularization rates at 12 months between DEB
and PTA (24% vs. 27.3%), limb salvage rates were
high (96.7% vs. 94.1%) in both groups.
Zeller et al. (14) should be congratulated for the
BIOLUX P-II (BIOTRONIK’S–First in Man study of the
Passeo-18 LUX drug releasing PTA Balloon Catheter
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1624vs. the uncoated Passeo-18 PTA balloon catheter in
subjects requiring revascularization of infrapopliteal
arteries) prospective, multicenter, randomized con-
trolled trial with independent clinical event adjudi-
cation and angiographic core lab for a study
designed to determine the superiority of 1 device
versus PTA alone. These studies are considered the
“crème de le crème” of clinical research, allowing
clinicians to compare treatments directly to one
another minimizing the effects of confounding on
cause and effect. These studies are in the minority
compared to single-arm, single-center device trials
or prospective device registries, which can conﬁrm
safety but not comparative effectiveness. Our ex-
pectations as clinicians in 2015 should be an in-
vestment in trials to demonstrate the comparative
safety and effectiveness of different devices, and we
should no longer settle for single-arm device trials
of safety. Unfortunately for paclitaxel DEB, this
study joins others in failing to meet criteria for
superiority versus PTA alone for angiographic and
hard clinical endpoints and supports the supposi-
tion of high restenosis rates but high limb salvage
rates with plain old balloon angioplasty alone
(15,16).
There are many deﬁciencies in the clinical research
design of studies in the treatment of CLI that must be
addressed moving forward. Most importantly, we
must come to consensus regarding the relevant end-
points and their deﬁnitions in CLI trials. This deﬁ-
ciency has been overtly recognized in the medical
community by Conte et al. (17) in their suggested
objective performance goals and clinical trial design
statement published in 2009 to evaluate catheter-
based treatment of CLI. They advocate for a primary
efﬁcacy endpoint deﬁned as 30-day death and major
adverse limb event (amputation or major reinter-
vention) occurring within 1 year adopted in part by
the study by Zeller et al. (14). Efforts to harmonize
and solidify relevant clinical trial and registry data
elements and deﬁnitions in the evaluation and
treatment for peripheral arterial disease were
recently addressed by the U.S. Food and Drug
Administration with multiple stakeholders and cul-
minated in the release of consensus deﬁnitions from
the Peripheral Academic Research Consortium (18).
This document advocates for a consistent use of
deﬁnitions and nomenclature across clinical trials in
the peripheral arterial disease space for more efﬁcient
regulatory evaluation and best practice guidelines
to inform clinical decisions.
However, one must ask, have we lost the forest
for the trees? With limb salvage rates at 1 year
exceeding 85% in most CLI trials evaluating all typesof treatments, such as PTA (cryoplasty, cutting bal-
loons, scoring balloons), drug-eluting stents for focal
tibial disease, atherectomy, ablation, cell therapy,
and no-option control patients is limb-salvage really
the endgame? We are well aware of the difﬁcult
lifestyle of our patients with CLI who come to our
appointments in their wheelchairs often propelled
by caregivers just after their biweekly wound care
appointment. Up to 70% of CLI patients are on
analgesia with continued pain that is hard to sup-
press and have quality-of-life scores worse than
cancer, chronic heart failure, and chronic kidney
disease (19). The Institute of Medicine envisioned a
more patient-centered health care system focused
on the patient’s functional status and health-related
quality of life (deﬁned as the patient’s perceived
physical, emotional, and social well-being and
function). Treatment of CLI should be focused on
improving health status in addition to limb preser-
vation, which is a refreshingly easy metric to ach-
ieve in contemporary CLI programs. Disease-speciﬁc
questionnaires such as the Peripheral Artery Ques-
tionnaire and the Walking Impairment Question-
naire are just a few of the validated tools in
assessing functional status and quality of life in
patients with lower extremity claudication; howev-
er, CLI-speciﬁc instruments that incorporate wound
care domains may be more comprehensive (20).
Most would agree that wound care is at least as
important to wound healing and limb salvage as
blood ﬂow is, yet efforts to standardize the care of
wounds in clinical practice or clinical trials has been
lacking. Current classiﬁcation schemes such as the
Fontaine stages and Rutherford categories are
insufﬁcient to capture the extent and severity of
nonhealing wounds. Perhaps the Society for
Vascular Surgery Lower Extremity Threatened limb
classiﬁcation system, which has been designed to
better deﬁne the disease burden based on the de-
gree of ischemia, wound extent, gangrene, and
infection, will allow better quantiﬁcation of wound
severity and allow measures of wound healing as an
endpoint in future trials of CLI care (21). Although
vessel patency and limb salvage are logical and
laudable endpoints to consider, until we routinely
include measures of wound healing and quality of
life to these trials, we will continue to miss the
forest for the trees in our patients with CLI.
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